Drug
Enzastaurin clinical trials
Also written LY317615.
Includes 11 studies of Enzastaurin hydrochloride.
- studies test it
- 50
- open now
- 0
- in phase 3
- 5
- first study started
- 2002
How studies write it
Studies that test it under each name
Name
Development codes
- LY317615
- 35
Studies by the year they started
50 studies that test it; most in 2007 (23)
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 10 |
| 2007 | 23 |
| 2008 | 5 |
| 2011 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 37
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 44 · Other 6
Eli Lilly and Company (41) · Denovo Biopharma LLC (2) · Eastern Cooperative Oncology Group (2) · Gynecologic Oncology Group (1) · Pediatric Brain Tumor Consortium (1) · Aytu BioPharma, Inc. (1) · National Cancer Institute (NCI) (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Often tested with
Tested in the same studies.
Bevacizumab (3) · Gemcitabine (2) · Temozolomide (2) · Carboplatin (2) · Pemetrexed (1) · Erlotinib (1) · Docetaxel (1) · Prednisone (1)
Studies
Open first, then newest update. How each study uses enzastaurin is read from its arms, and is right about nine times in ten.
Testing it · 50
- Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™CompletedPhase 3Denovo Biopharma LLCNCT03263026Written as Enzastaurin Hydrochloride
- A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1CompletedPhase 3Denovo Biopharma LLCNCT03776071Written as Enzastaurin Hydrochloride
- Investigate Efficacy, Safety, and Pharmacokinetics of Enzastaurin for the Prevention of Arterial Events in Patients With Vascular Ehlers-Danlos Syndrome.SuspendedPhase 3Aytu BioPharma, Inc.NCT05463679Written as Enzastaurin
- Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With ChemotherapyCompletedPhase 2Eli Lilly and CompanyNCT00533429Written as enzastaurin
- First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2Eli Lilly and CompanyNCT00308750Written as enzastaurin
- A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung CancerCompletedPhase 1/2Eli Lilly and CompanyNCT00452413Written as enzastaurin
- Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal CancerCompletedPhase 2Eli Lilly and CompanyNCT00420381Written as enzastaurin
- Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and ChemotherapyCompletedPhase 2Eli Lilly and CompanyNCT00428714Written as enzastaurin
- A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer PatientsCompletedPhase 2Eli Lilly and CompanyNCT00466440Written as enzastaurin
- Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation TherapyCompletedPhase 2Eli Lilly and CompanyNCT00415363Written as enzastaurin
- Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + PlaceboTerminatedPhase 2Eli Lilly and CompanyNCT00538681Written as enzastaurin
- A Study for Participants With Relapsed Cutaneous T-Cell LymphomaCompletedPhase 2Eli Lilly and CompanyNCT00744991Written as Enzastaurin
- A Study for Patients With Non-Hodgkin's LymphomasCompletedPhase 2Eli Lilly and CompanyNCT00542919Written as enzastaurin
- Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill")CompletedPhase 2Eli Lilly and CompanyNCT00391118Written as enzastaurin
- A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or LymphomaCompletedPhase 1Eli Lilly and CompanyNCT01432951Written as Enzastaurin
- Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant GliomasCompletedPhase 2Eli Lilly and CompanyNCT00586508Written as enzastaurin
- Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast CancerTerminatedPhase 2Eli Lilly and CompanyNCT00536939Written as Enzastaurin
- A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former SmokersCompletedPhase 2Eli Lilly and CompanyNCT00414960Written as Enzastaurin
- A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple MyelomaCompletedPhase 2Eli Lilly and CompanyNCT00718419Written as Enzastaurin
- Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic CancerCompletedPhase 2Eli Lilly and CompanyNCT00267020Written as enzastaurin
Codes
What other systems call enzastaurin · ClinicalTrials.gg INT004827
- MeSH (NLM) C504878enzastaurinOne source NLM
- UNII (FDA) UC96G28EQFENZASTAURINConfirmed FDA, NLM, Wikidata
- Wikidata Q5381479enzastaurinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77392EnzastaurinOne source FDA
- DrugBank DB06486One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C504878 | enzastaurin | One source NLM |
| UNII (FDA) | UC96G28EQF | ENZASTAURIN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5381479 | enzastaurin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77392 | Enzastaurin | One source FDA |
| DrugBank | DB06486 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.